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A B S T R A C T
Retinitis pigmentosa (RP) is one of the most common retinal degenerative conditions aﬀecting people
worldwide, and is currently incurable. It is characterized by the progressive loss of photoreceptors, in which
the death of rod cells leads to the secondary death of cone cells; the cause of eventual blindness. As rod cells die,
retinal-oxygen metabolism becomes perturbed, leading to increased levels of reactive oxygen species (ROS) and
thus oxidative stress; a key factor in the secondary death of cones. In this study, norgestrel, an FDA-approved
synthetic analog of progesterone, was found to be a powerful neuroprotective antioxidant, preventing light-
induced ROS in photoreceptor cells, and subsequent cell death. Norgestrel also prevented light-induced
photoreceptor morphological changes that were associated with ROS production, and that are characteristic of
RP. Further investigation showed that norgestrel acts via post-translational modulation of the major antioxidant
transcription factor Nrf2; bringing about its phosphorylation, subsequent nuclear translocation, and increased
levels of its eﬀector protein superoxide dismutase 2 (SOD2). In summary, these results demonstrate signiﬁcant
protection of photoreceptor cells from oxidative stress, and underscore the potential of norgestrel as a
therapeutic option for RP.
1. Introduction
Retinitis pigmentosa (RP) is a group of highly heterogeneous
inherited retinal diseases, all of which comprise progressive death of
rod and cone photoreceptors via several diﬀerent signaling cascades,
including apoptosis, autophagy and necrosis [1,2]. Currently, disease
causing-mutations have been identiﬁed in 60 rod photoreceptor-genes
[The Retinal Information Network (RetNet), https://sph.uth.edu/
retnet/, July 2016]. Despite the various genes involved, all cases of
RP are characterized by death of rod photoreceptors followed by
secondary gradual death of cone cells, which eventually leads to total
blindness [3,4]. Oxidative stress has been shown to be a key
contributor to the progression of RP and many other retinopathies
[5–8], owing to the fact that photoreceptors are the most metabolically
active cells in the body, consuming more oxygen per gram than any
other tissue [9]. Many studies both in vivo and in vitro suggest a key
reason for secondary-cone cell death in RP is oxidative damage due to
the increasing oxygen levels, and thus reactive oxygen species (ROS), as
rod cells die [6,10–15]. On top of this, it has been demonstrated that
ROS produced due to light exposure can potentiate the degeneration of
the retina in inherited and age-related retinopathies, including RP [16–
20].
One of the primary cellular responses to oxidative stress is
activation of the ubiquitously expressed basic-leucine-zipper transcrip-
tion factor NF-E2-related factor-2 (Nrf2) [21,22]. Upon liberation from
its repressor, kelch-like ECH-associated protein 1 (KEAP1), Nrf2
translocates into the nucleus where it binds antioxidant response
elements (AREs), bringing about the up-regulation of various antiox-
idant, detoxifying and cytoprotective genes [22–26]. Studies investi-
gating the anti-oxidant eﬀects of Nrf2 in the retina have demonstrated
its importance in protecting retinal ganglion cells following optic nerve
crush [27], and in slowing the progression of diabetic retinopathy [28].
Although few studies have focused on RP, a recent investigation by
Nakagami and colleagues using a rabbit model demonstrated how
activation of Nrf2 and upregulation of its eﬀector proteins delayed the
loss of photoreceptor cells [29].
Nrf2 can be regulated by various signaling molecules including
progesterone, a pleiotropic neuroprotective hormone. It has also been
shown that progestin, as part of hormone replacement therapy (HRT),
increases the expression of the Nrf2-regulated superoxide dismutase
antioxidant enzymes (SODs) [30,31], while in the heart, progesterone
upregulates the Nrf2 eﬀector NAD(P)H quinone oxidoreductase 1
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(NQO1) [32]. Progesterone also exerts antioxidant eﬀects in experi-
mental models of traumatic brain injury, which include increasing SOD
activity [33–35].
We have previously demonstrated the neuroprotective eﬀects of
norgestrel, a synthetic analog of progesterone, in both the inherited RP
model, and the light-damage model of retinal degeneration. Norgestrel
rescues photoreceptors from cell death via a mechanism which includes
upregulation of the neurotrophic factors bFGF and LIF [36,37]. Here,
we sought to investigate if the activities of norgestrel in light-induced
retinal degeneration include modulation of the redox environment. We
provide evidence that norgestrel increases expression and activation of
Nrf2 via phosphorylation on serine 40, increases expression of its
target antioxidant superoxide dismutase 2 (SOD2), and reduces
mitochondrial oxidative stress.
2. Material and methods
2.1. Mice
All animals were maintained and handled in accordance with the
Association for Research in Vision and Ophthalmology statement for
the Use of Animals in Ophthalmic and Vision Research. Experiments
were performed on balb/c mice obtained from Harlan Olac (Bicester,
UK). Mice were euthanized by cervical dislocation. All procedures were
approved by the Health Products Regulatory Authority (HPRA),
Ireland.
2.2. Light damage model
The light-damage model was performed as previously described
[37]. Brieﬂy; Balb/c mice were born into and maintained in dim cyclic
light less than 10 lx (12 h on/12 h oﬀ). At 4–7 weeks of age, mice were
dark adapted for 18 h prior to exposure to damaging light. Mice
received intraperitoneal injections (i.p.) of 50 μL vehicle (25 μL
dimethylsulfoxide/25 μL peanut oil) or 50 μL norgestrel (100 mg/kg),
1 h prior to light-damage. Immediately prior to light-damage, their
pupils were dilated with 0.5% cyclopentolate under red light. Retinal
light-damage was then induced by exposure to cool white ﬂuorescent
light (5000 lx) for 2 h. Following this, the mice were placed in the dark
for 6, 24 or 48 h, as indicated, prior to euthanasia.
2.3. Eye sections preparation
Enucleated eyes were ﬁxed in 4% paraformaldehyde (PFA) for 1.5 h
followed by cryo-protection in 30% sucrose at 4 °C overnight. Eyes
were then frozen in Shandon™ Cyrochrome™ (ThermoFisher
Scientiﬁc) and 7 µm sections were then cut using a cryostat (Leica
CM1950; Leica Co., Meath, Ireland). Sections were stored at −80 °C
until use.
2.4. Microscopy
Retinal sections were viewed using a Leica DM LB2 microscope
with Nikon Digital Sight DS-U2 camera, using 40× and 100× objec-
tives. Images were taken using the software NIS-Elements version 3.0,
Nikon, Japan. Immunoﬂuorescence on retinal sections was performed
on at least three mice of each group, at each time-point. Identical
microscope settings were used when obtaining images across all
timepoints and treatments. Images shown are those taken of the
central retina.
2.5. Quantiﬁcation from immunohistochemically-labeled sections
Quantiﬁcation of outer nuclear layer (ONL) thickness and ﬂuores-
cence intensity measurements were carried out using ImageJ software,
as previously described [38,39]. Average ONL thickness was measured
by taking measurements from at least 20 sections per mouse. Per
section, three distinct measurements were taken and averaged. Nrf2
and SOD2 ﬂuorescence intensity measurements were taken from the
same region and in the same orientation, at 40× magniﬁcation. These
images were used to create plot proﬁles of the marker of interest and
the area under the curve was measured as a readout of ﬂuorescence
intensity.
2.6. Apoptosis detection by terminal deoxynucleotidyl transferase-
mediated biotinylated dUTP nick end labeling (TUNEL)
DNA strand breaks in photoreceptor nuclei were detected by
terminal deoxynucleotidyl transferase-mediated dUTP nick end label-
ing (TUNEL). Frozen sections (7 µm) were incubated with terminal
deoxynucleotidyl transferase (Promega, MyBio Ltd., Kilkenny,
Republic of Ireland) and ﬂuorescein-12-dUTP (Roche, Lewes, UK)
according to manufacturers’ instructions at 37 °C for 1 h. Sections were
counter-stained with Hoechst (1 μg/mL) to visualize the nuclei,
mounted and viewed under a ﬂuorescence microscope (Leica DM
LB2; Leica, Nussloch, Germany).
2.7. Immunoﬂuorescent staining
Frozen sections were brought to room temperature, rehydrated in
PBS (137 mM NaCl, 2.7 mM KCL, 10 mM NaPO4, 1.8 mM KH2PO4),
permeabilized in PBS with 5% donkey serum and 0.1% Triton X-100
for 30 min at room temperature, followed by blocking in PBS with 5%
donkey serum. Subsequently, sections were incubated with primary
antibody or lectin solutions overnight at 4 °C (Table 1). Antibody
binding was detected by using conjugated secondary antibodies (Alexa
Fluor 488; Invitrogen, Carlsbad, CA) at a dilution of 1/500 for 1 h at
room temperature. Sections incubated with secondary antibody-only
conﬁrmed positive immunolabelling with primary antibodies (data not
shown). Hoechst 33,342 (1 μg/mL; Sigma-Aldrich) was used to coun-
terstain the nuclei. Sections were mounted with Mowiol mounting
medium (Sigma-Aldrich) and viewed under a ﬂuorescence microscope
(Leica DM LB2; Leica).
2.8. Assessment of ROS using dihydroethidium (DHE)
Intracellular ROS were evaluated in situ using dihydroethidium
(DHE), as previously described [40–42]. Once in contact with super-
oxide radicals, DHE is converted to ethidium which intercalates with
DNA and emits red ﬂuorescence at approximately 600 nm. Following
light-damage, mice received two intraperitoneal injections of 20 mg/kg
DHE (Molecular Probes, Life Technologies), 30 min apart. Injections
were carried out 3.5/4 h prior to euthanasia, using as little light as
possible. Mice were then returned to the dark until euthanized; at 6, 24
or 48 h post-light-damage. Eyes were enucleated, ﬁxed, cryo-sectioned
and re-hydrated as described above, followed by counter-staining with
Table 1
primary antibodies/lectins used.
Antibody/
Lectin
Supplier Catalogue # Dilution/
Concentration
PNA-FITC Vector
Laboratories
FL-1071 1:500
Rhodopsin EMDMillipore AB9279 1:200
Nrf2 Abcam ab31136 1:200 IF
1:1000 western blot
SOD2 Abcam ab13553 1:200
SOD1 Abcam ab13498 1:200
phospho-Nrf2
(S40)
Abcam Ab76026 1:100 IF
1:5000 western blot
GAPDH Cell Signaling 5174 1:1000
Histone H3 Abcam Ab12079 1 µg/mL
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primary antibody or TUNEL, and Hoechst; as described in
Immunoﬂuorescent Staining above. DHE staining was examined in
the red channel; excitation: 543 nm, emission > 590 nm.
2.9. Flow cytometry
2.9.1. Single cell suspension preparation and assessment of cell
viability
Following euthanasia, the retinas from enucleated eyes were
dissected in cold Dulbecco's modiﬁed Eagle medium (DMEM) under
as little light as possible. Single-cell suspensions (SCSs) were made by
digesting each retina in 2.5 mL of Trypsin-EDTA solution (0.25%)
containing 50 μL deoxyribonuclease II (DNaseII) (10,000 units/mL)
from bovine spleen (both Sigma, Arklow, Ireland) for 15 min at 37 °C.
This solution was then decanted, and 2.5 mL DMEM containing 50 μL
DNase II was added to retinas. Homogenization was performed by
pipetting up and down 10 times using a Pasteur pipette. Large debris
was allowed to settle, and 2 mL of single-cell suspension were collected
and placed into a FACs tube (BD Biosciences) to be loaded with
MitoSox. The cell viability of the SCSs was assessed by tryphan blue-
exclusion assay (Sigma, cat.# 15250061) using a haemocytometer.
2.9.2. Assessment of SCS quality
To verify the SCSs comprised intact rather than fragmented cells,
cytospin preparations were made using 200 μL of each SCS with a
Shandon CytoSpin 11 Cytocentrifuge (Shandon). Cytospins were then
incubated with rhodopsin antibody (Table 1) and Hoechst 33,342
(1 μg/mL; Sigma-Aldrich) as described above in Immunoﬂuorescent
staining.
2.9.3. MitoSox assessment
Mitochondrial ROS levels in light-damaged retinas were assessed
using the intracellular mitochondrial superoxide probe, MitoSox
(Molecular probes, Life Technologies). Single cell suspensions were
loaded with 5 µM MitoSox for 15 min at 37 °C, and ﬂuorescence was
measured using a Becton-Dickinson FACScan ﬂow cytometer.
MitoSOX Red was excited by laser at 488 nm, and the data collected
at FSC, SSC, 670LP (FL3) channel. 10,000 events were counted in the
gated photoreceptor region. Cell debris, as represented by distinct low
forward and side scatter, were gated out for analysis. Results were
analyzed using FlowJo software (Trustees of Leland Stanford Jr.
University).
2.10. RNA isolation, cDNA synthesis, and real-time PCR
Total RNA (tRNA) isolation from retinas was carried out using an
RNeasy Midi Kit (Qiagen) according to manufacturer's instruction,
including DNase treatment to digest residual genomic DNA. Retinas
were homogenized using a pellet pestle cordless motor (Sigma, cat#
Z359971). RNA was reverse transcribed using the QuantiTect Reverse
Transcription Kit (Qiagen). Real time PCR (rtPCR) was performed
using murine QuantiTect Primer Assays (Qiagen) and SYBR Green
JumpStart Taq ReadyMix (Sigma-Aldrich) in an ABI Prism 7900HT
Sequence Detection System (Applied Biosciences). mRNA values were
normalized to the geometric mean of three endogenous reference
genes; βactin, gapdh and hprt. Relative changes in gene expression
were quantiﬁed using the comparative Ct (ΔΔCt) method as described
by Livak and Schmittgen [43].
2.11. Western blotting
Subcellular protein fractionation was carried out on snap-frozen
retinas using a tissue-speciﬁc kit (Thermo Scientiﬁc, cat# 87790).
100 mg of retinas (~4 retinas) from each group and each time point
were pooled and homogenized using a pellet pestles cordless motor
(Sigma, cat# Z359971). Cellular fractions were prepared according to
kit instructions, with replacement of the Halt™ Protease Inhibitor
Cocktail (included in the kit), with Halt™ Protease and Phosphatase
Inhibitor Cocktail (Sigma, cat~78440). Total protein concentration of
each fraction was determined by Bradford assay, using BSA as
standard. Equivalent amounts of protein were resolved on sodium
dodecyl sulphate–polyacrylamide gel electrophoresis (SDS-PAGE) in
4X Protein Sample Loading Buﬀer (LI-COR, cat# P/N 928-40004) and
then transferred onto nitrocellulose membranes (Schleicher & Schuell,
Whatman, Dassel, Germany). Membranes were blocked with Odyssey
TBS Blocking Buﬀer (LI-COR, cat# P/N 927–50000) for 1 h at RT and
then incubated at 4 °C overnight with primary antibody (Table 1).
Membranes were subsequently washed three times for 5 min in Tris-
buﬀered saline/0.1% Tween-20 (TBST) before adding appropriate
Alexa Fluor ﬂuorescent secondary antibodies diluted 1:10,000, in
Odyssey TBS Blocking Buﬀer/TBST solution. Blots were scanned using
the Odyssey Infrared Imaging System (LI-COR Biosciences, UK) for
ﬂuorescent detection of the secondary antibodies. Fluorescence signal
intensity was quantiﬁed using Image Studio Lite software (LI-COR
Biosciences, UK).
2.12. Statistical analyses
Student's t-test assuming unequal variances was used to determine
whether there was a signiﬁcant diﬀerence between the two sample
means.
3. Results
3.1. Norgestrel rescues photoreceptor cells from light-induced ROS
production and subsequent cell death
We have previously described how norgestrel protects photorecep-
tor cells from light-induced cell death [37]. To investigate whether
norgestrel also reduces light-induced ROS, vehicle or norgestrel treated
mice were light-damaged (LD) and subsequently given intraperitoneal
injections of dihydroethidium (DHE). DHE is a sensitive indicator of
ROS in situ. It is a non-speciﬁc superoxide marker, which, once in the
presence of ROS, is converted to ethidium bromide and binds DNA,
emitting a red ﬂuorescence.
At 6 h (Fig. 1Ai), 24 h (Fig. 1Aii) and 48 h (Fig. 1Aiii) post-LD,
vehicle (veh) treated mice are positive for DHE ﬂuorescence, indicative
of ROS production. DHE is visible in the photoreceptor layer (PRL),
which houses the inner and outer segments of the rods and cones, and
the outer nuclear layer (ONL), which comprises the cell bodies of rods
and cones. At all time-points, norgestrel (norg) inhibits DHE. Here,
and in subsequent ﬁgures, DHE ﬂuorescence is also observed within
the retinal pigment epithelium (RPE), which is sensitive to light-
induced oxidative stress [44]. TUNEL within the ONL shows photo-
receptor cell death in vehicle treated mice at 24 h and 48 h post-LD,
which is also inhibited by norgestrel, as expected. The ONL is visibly
thinner in vehicle treated mice 24 h and 48 h after LD, as assessed by
Hoechst staining of cell nuclei. ONL thickness was measured to
quantify the reduction in cell death due to norgestrel (Fig. 2B).
3.2. Norgestrel rescues light-induced photoreceptor morphological
damage
We have previously shown that norgestrel preserves photoreceptor
morphology in the rd10 model of RP, which translates into preserva-
tion of function as measured by electroretinograms [37]. Here, we
sought to investigate if light-damage (LD) induces structural damage to
the photoreceptors similar to the disease model, whether this correlates
with ROS production, and whether norgestrel can prevent such
damage. The morphology of the photoreceptors was investigated at
24 and 48 h post-LD (Fig. 2); the times at which cell death is observed
(Fig. 1). Rod morphology was assessed by immunoﬂuorescent staining
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with anti-rhodopsin (Rho), while cone morphology was assessed by
staining with the lectin peanut agglutinin (PNA). PNA binds speciﬁcally
to carbohydrates on the plasma membranes of cone inner and outer
segments, as well as their synaptic pedicles that reside within the outer
plexiform layer (OPL) [45].
LD markedly reduced photoreceptor cell density in vehicle (veh)
treated mice compared to those that received norgestrel (norg), with
the remaining photoreceptor layer displaying abnormalities in length
and structure (Fig. 2Ai, ii and Bi, ii, upper panels). By 24 h post-LD,
cone cells had begun breaking down in vehicle treated mice, becoming
fragmented and swollen in appearance (Fig. 2Ai, upper panels), a
phenomenon shown to occur in the rd10 model of RP [46]. By 48 h,
this aberrant morphology was more advanced, with no synaptic
pedicles visible in the OPL (Fig. 2Bi, upper panels). In contrast, cone
cell structure was preserved following LD in norgestrel treated mice,
with cells retaining their characteristic neuronal morphology (Fig. 2Ai,
Bi, lower panels).
At 24 h post-LD rod cell morphology appears more abnormal than
that of cones in vehicle treated mice (Fig. 2Aii, upper panels), in
accordance with the disease model of RP where cone cell death is
secondary to that of rods [3,4]. Rhodopsin is expressed in rod outer
segments, but immunoreactivity appears closer to the ONL in vehicle
compared to norgestrel treated mice, (Fig. 2Aii, Bii, top panels). This
suggests that rhodopsin has de-localized to the inner segments, a
phenomenon also observed during retinal degeneration in inherited RP
models [47]. By 48 h, rhodopsin immunoreactivity is reduced in vehicle
compared to norgestrel treated mice (Fig. 2Bii), as rod cell death
increases. At both time-points, norgestrel restores rod morphology;
with uniform rhodopsin staining that is localized further from the ONL
(Fig. 2Aii, Bii, lower panels). Counter-staining of DHE with PNA or
rhodopsin illustrates that ROS production correlates with morpholo-
gical changes to the photoreceptors.
3.3. Norgestrel reduces light-induced mitochondrial ROS
Photoreceptors have a densely packed population of mitochondria
within their inner segments, and as such have a high metabolic demand
[48]. This demand is met by mitochondrial oxidative phosphorylation
(OXPHOS), perturbation of which generates excess levels of ROS and is
implicated in various neurodegenerative diseases, including RP [49].
To determine if norgestrel can reduce light-induced mitochondrial-
speciﬁc ROS, ﬂow cytometry was carried out using single-cell suspen-
sions (SCSs) from retinas of light-damaged (LD) mice loaded with the
ﬂuorescent probe MitoSox (Fig. 3). MitoSox is a modiﬁed derivative of
DHE, which is targeted speciﬁcally to the mitochondria [50]. Upon
oxidation, MitoSox is converted to mito-2-hydroethidium, which binds
mitochondrial DNA and emits a red ﬂuorescence [51]. Unlike DHE,
MitoSox cannot be administered to live animals, hence this approach
was taken. Initially, the photoreceptor population was identiﬁed by
carrying out ﬂow cytometry on retinas of untreated LD mice (48 h post-
LD) compared with untreated mice which were not subjected to LD
(healthy) (Fig. 3A). 10,000 events were counted in both samples. The
population present in the healthy cells (78.8%) (ﬁgure Ai), that had
reduced (16.6%) in the LD mice (ﬁgure Aii), was deemed to be
photoreceptors based on the results in Fig. 1, in which cell death is
exclusively visualized within the ONL by TUNEL assay. This region was
gated in all subsequent experiments. Following LD, MitoSox ﬂuores-
cence is reduced in norgestrel treated mice at 6 h (Fig. 3Bi), 24 h
(Fig. 3Ci) and 48 h (Fig. 3Di) as represented by histogram overlays.
Taking all experiments, the median ﬂuorescence intensity of MitoSox
was signiﬁcantly diﬀerent between vehicle and norgestrel treated mice
at 6 h; p= < 0.001 (Fig. 3Bii), 24 h; p= < 0.0042 (Fig. 3Cii) and 48 h p=
< 0.0044 (Fig. 3Dii).
To ensure the retinal cells remained viable following the SCS
preparation tryphan blue-exclusion assays were performed. This test
is based on the concept that viable healthy cells do not take up
impermeable dyes, whereas dead or compromised cells do. Cell
viability was found to be approximately 80% (Fig. 3E).
To further validate the quality of the SCS preparations, and to
ensure cells remain intact without becoming fragmented, cytospins
were made using SCSs from retinas of healthy mice. Rhodopsin
immunoreactivity merged with Hoechst staining veriﬁed the photo-
receptor cells were indeed intact (Fig. 3Fi–iii).
3.4. Norgestrel increases the expression of Nrf2 and SOD2, but not
SOD1
We next sought to investigate if the antioxidant eﬀects of norgestrel
following LD include modulation of the expression of Nrf2 and its
eﬀector proteins SOD1 and SOD2. Nrf2 was chosen as it is often the
ﬁrst port of call when cells come under oxidative stress, and along with
the SODs has been shown to be regulated by progesterone [31–35].
SOD1 and SOD2 scavenge hydrogen peroxide in the cytosol and
mitochondria respectively [52,53]. Employing immunoﬂuorescent
staining of retinal sections, we found that norgestrel markedly in-
creases both Nrf2 and SOD2 expression in photoreceptor cells. Nrf2
Immunoreactivity is increased in the photoreceptor layer (PRL) at 6 h
(Fig. 4Ai), 24 h (Fig. 4Bi) and 48 h (Fig. 4Ci) post-LD. SOD2 expression
is also increased in the PRL at all time-points studied (Fig. 4A,B,C, ii).
Quantiﬁcation of ﬂuorescence intensity shows that these increases in
Nrf2 and SOD2 are signiﬁcant at all time-points (Fig. 4D). Norgestrel
fails to increase the expression of SOD1 any time post-LD (Figs. Aiii,
Biii and Ciii). ROS were also visualized by DHE ﬂuorescence.
3.5. Norgestrel modulates Nrf2 expression at the post-translational
level
We lastly sought to investigate the mechanism of Nrf2 up-regula-
tion by norgestrel. Firstly, we looked at the eﬀect of norgestrel on Nrf2
transcription by means of quantitative real time PCR (qRT-PCR). At all
time-points post-LD, no change was observed in nrf2 expression
between vehicle and norgestrel treated mice (Fig. 5A). Next, we
investigated the eﬀect of norgestrel on Nrf2 at the post-translational
level. Indeed, Nrf2 is regulated mainly at the post-translational level. It
is constitutively expressed, and under basal conditions the majority of
the population is bound to the inhibitor KEAP1, which sequesters Nrf2
within the cytoplasm and promotes its constant degradation by the
ubiquitin protease system (UPS) via the E3 ligase Cul-3 [54]. In
response to stimuli Nrf2 can also be activated in various ways,
including phosphorylation. Nrf2 contains many potential phospho-
sites, which may be targets for diﬀerent kinases [55]. One veriﬁed Nrf2
kinase is protein kinase C (PKC) which phosphorylates Nrf2 on serine
40 (S40), thereby disrupting its interaction with KEAP1, and enabling
it to translocate into the nucleus [56,57]. Firstly, we investigated
Fig. 1. Norgestrel prevents light-induced ROS production and subsequent cell death. Balb/c mice were given intraperitoneal injections of vehicle (veh) or vehicle containing 100 mg/kg
norgestrel (norg) 1 h prior to light damage (LD) and were euthanized at 6 h, 24 h or 48 h post-LD. Approximately 4 h before euthanasia, mice received two intraperitoneal injections of
20 mg/kg dihydroethidine (DHE), 30 min apart. Ocular sections were prepared and assessed by microscopy as described in Methods. A; DHE ﬂuorescence (red), indicative of ROS
production, and TUNEL staining (green), indicative of cell death, were assessed in the retinas of mice treated with vehicle (veh) or norgestrel (norg) at 6 h (Ai), 24 h (Aii) and 48 h (Aiii)
post-LD. Hoechst staining of retinal nuclei allows orientation of retinal layers, and shows changes in the thickness of the ONL following LD. B; graphical representation of ONL thickness
at 24 and 48 h post-LD in vehicle (veh) or norgestrel (norg) treated mice. RPE; retinal pigment epithelium, PRL; Photoreceptor layer, ONL; outer nuclear layer, INL; inner nuclear layer,
RGL; retinal ganglion cell layer. Images are representative of at least n=3. Error bars denote ± SEM from three independent experiments Scale bar=50 µm. *p= < 0.05. (For
interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
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whether norgestrel has any eﬀect of Nrf2 phosphorylation and thus
nuclear translocation. Cytosolic and nuclear fractions from whole
retinal lysates of mice treated with vehicle (veh) or norgestrel (norg)
prior to LD were probed for pNrf2 (S40) expression by means of
western blot analysis (Fig. 5B). pNrf2 is markedly increased in the
nuclear fractions at all times post-LD following norgestrel treatment,
while total Nrf2 is only marginally increased, or not at all by 48 h. We
then employed immunoﬂuorescent staining of retinal sections to look
at the expression of pNrf2 in the photoreceptors speciﬁcally (Fig. 5C).
Compared to vehicle treated mice, norgestrel elevated the levels of
pNrf2 within the ONL at 6 h (Fig. 5Ai), 24 h (Fig. 5Aii) and 48 h
(Fig. 5Aiii).
Fig. 2. Norgestrel rescues photoreceptors from light-induced structural damage. Balb/c mice were given intraperitoneal injections of vehicle (veh) or vehicle containing 100 mg/kg
norgestrel (norg) 1 h prior to light damage (LD) and were euthanized at 24 h or 48 h post-LD. Approximately 4 h before being euthanasia, mice received two intraperitoneal injections of
20 mg/kg dihydroethidine (DHE), 30 min apart. Ocular sections were obtained and assessed by microscopy as described in Methods. A, B; the eﬀect of LD on photoreceptor morphology
was assessed in retinas of mice treated with vehicle (veh) or norgestrel (norg) and euthanized 24 (A) or 48 h (B) post-LD. Cone morphology was assessed by peanut agglutinin (PNA)
binding (Ai, Bi). Rod morphology was assessed by rhodopsin staining (Aii, Bii). DHE counter-ﬂuorescence (red) is also shown. PRL; Photoreceptor layer, ONL; outer nuclear layer, OPL;
outer plexiform layer, INL; inner nuclear layer. Images are representative of at least n=3. Scale bar=50 µm. (For interpretation of the references to color in this ﬁgure legend, the reader
is referred to the web version of this article.)
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Fig. 3. Norgestrel decreases light-induced mitochondrial ROS. Balb/c mice were given intraperitoneal injections of vehicle (veh) or vehicle containing 100 mg/kg norgestrel (norg) 1 h
prior to light damage (LD) and were euthanized at 6 h, 24 h or 48 h post-LD. Retinas were removed from the eyes, digested and homogenized into single-cell suspensions (SCSs) and
loaded with MitoSox, as described in Methods. MitoSox ﬂuorescence was assessed by ﬂow cytometry. A; initially, the photoreceptor population was identiﬁed by counting 10,000 events
in SCSs from un-treated healthy mice (i) or un-treated mice 48 h after being subjected to LD (ii). Forward scatter (FSC) plotted against side scatter (SSC) shows the photoreceptor (PR)
cell population in healthy mice (78.8%) (Ai) is dramatically reduced (16.6%) in the retinas of LD mice (Aii). B (6 h); C (24 h); D (48 h); representative histogram overlays show MitoSox
ﬂuorescence in norgestrel (norg) treated mice compared to vehicle (veh) (i). Graphical representations of the median ﬂuorescence intensity (MFI) of MitoSox in vehicle (veh) or
norgestrel (norg) treated mice (ii). E; cell viability of the SCSs was measured by tryphan blue-exclusion assay. F; cytospin preparations of SCSs from healthy mice were assessed for
rhodopsin immunoreactivity and visualized at 40× magniﬁcation (i, ii) (scale bar=50 µm) or 10× magniﬁcation (iii) (scale bar=25 µm). All results are representative of at least n=3. **p=
< 0.01, ***p= < 0.001. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
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4. Discussion
Photoreceptor cell death is the collective end-point for all cases of
RP, irrespective of the underlying genetic cause. As RP progresses,
phototransduction is reduced due to the disease-causing mutation and
the rod photoreceptors cannot utilize the oxygen available to them. As
the photoreceptor layer becomes progressively more disorganized this
is potentiated, resulting in hyperoxia within the outer retina and the
consequent initiation of cell death pathways [58,59]. Although the
disease-causing mutation resides within rod genes, it is the secondary
loss of cones that leads to total blindness. The mechanism behind this
is not fully understood, but it is known that oxidative stress is a key
factor [6–8,41,60]. Gene therapy is a promising therapeutic approach
for RP, however targeting the multitude of RP-related genes is complex
and so ROS pathways provide viable indiscriminate therapeutic targets,
where the aim is to retard retinal degeneration and preserve vision. If
cone cells could be saved, patients could lead a relatively normal life,
with good vision in bright conditions.
The steroid hormone progesterone is a potent neuroprotective
agent, and has recently been shown to reduce oxidative stress in a
model of repeated mild brain injury [35]. We have previously demon-
strated how the synthetic progestin norgestrel is neuroprotective in the
compromised retina using the rd10 model of RP, and the light-damage
model of retinal degeneration [36,37]. Norgestrel acts via upregulation
of the neurotrophic factors bFGF and LIF, the latter being a potent
neurotrophic factor which, interestingly, has been shown to have
antioxidant eﬀects in the retina [61]. Here, we further expand on the
neuroprotective actions of norgestrel in the retina, investigating its
eﬀects on oxidative stress using the light-damage model of retinal
degeneration, a well-established paradigm [62]. Light-damage caused
the production of intracellular ROS in photoreceptor cells, as visualized
by DHE ﬂuorescence, which was prevented by pre-treatment with
norgestrel (Fig. 1). Due to the non-speciﬁcity of DHE [63], we refer
here to the detection of ROS, rather than superoxide. In vehicle-only
treated mice, total ROS is evident in the PRL and ONL. Within the PRL
are the inner segments of the photoreceptor cells which are high in
mitochondria [48], thus DHE ﬂuorescence here is suggestive of
mitochondrial ROS. As previously reported [37], norgestrel also
inhibited light-induced cell death, as visualized by TUNEL assays.
Light-induced ROS production preceded cell death, supporting the
hypothesis that oxidative stress is a key contributor to photoreceptor
loss.
As RP advances and photoreceptors progressively degenerate, the
cells undergo various structural changes. Rod cells exhibit de-localiza-
tion of rhodopsin [47], while cone inner and outer segments become
fragmented and swollen [46]. Cone pedicles are also lost, due to
perturbed synaptic connectivity within the OPL [64]. These phenom-
ena, characteristic of structural changes during RP, are observed
coinciding with ROS production following light-damage (Fig. 2).
Moreover, abnormalities in rod cell structure appear more advanced
than that of cones at 24 h post light-damage (Fig. 2A), as is observed in
RP models, where ROS derived from dying rod cells is a key factor in
cone cell death [6,10,11]. All structural aberrations were completely
prevented by norgestrel; which maintained normal photoreceptor
morphology and ONL thickness (Fig. 2).
Having looked at total intracellular ROS using DHE, we sought to
investigate whether mitochondrial-derived ROS plays a part in light-
induced photoreceptor degeneration (Fig. 3). Indeed, it has been shown
to play a major role in the development of other retinopathies, with
studies suggesting that mitochondrial-derived superoxide is the pri-
mary source of ROS in diabetic tissue, and is responsible for initiating
other ROS signaling pathways [65,66]. We show here that light-
damage indeed generates the production of mitochondrial ROS within
the photoreceptors which is signiﬁcantly reduced by norgestrel
(Fig. 3B). Unlike the complete inhibition of DHE ﬂuorescence
(Fig. 1), norgestrel did not abolish MitoSox ﬂuorescence. The diﬀer-
ence here is likely due to that fact that ﬂow cytometry is a far more
sensitive application. Also, the preparation of single-cell suspensions
may introduce ROS, and the reduction of light-induced mitochondrial-
ROS by norgestrel may appear greater if it could be assessed in situ.
Again, like DHE, MitoSox is a non-speciﬁc superoxide probe [63], and
so we refer to the detection of general ROS.
Having established that norgestrel can reduce mitochondrial-ROS
within photoreceptors, we sought to investigate the mechanism behind
this. Given that the KEAP1-Nrf2 pathway is one of the most important
in protecting retinal cells from endogenous- and exogenous-induced
oxidative stress [26], and that Nrf2 is paramount to normal mitochon-
drial function [67], we looked at the expression of Nrf2 in the stressed
retina following norgestrel treatment. To date, most studies on Nrf2 in
the context of retinopathies have been done using AMD models, where
photoreceptor loss is secondary to degeneration of the retinal pigment
epithelium (RPE). It has been shown that the aging RPE exhibits
dysregulated Nrf2 signaling, leading to impaired induction of antiox-
idant genes [68], while knockout of nrf2 in otherwise healthy mice
increases the susceptibility of the outer retina to age-related degenera-
tion [69]. Similarly, activation of Nrf2 by administration of sulfor-
aphane has been shown to protect RPE cells from photo-oxidative
damage [70]. Here, we investigated the expression of Nrf2 in photo-
receptor cells following light-induced oxidative stress. While minimal
Nrf2 was observed in vehicle treated mice at 6 h post light-damage,
with none at 24 h or 48 h, norgestrel induced Nrf2 expression in the
photoreceptor layer and sustained it for at least 48 h following the
insult (Fig. 4Ai, Bi and Ci).
Following on from this, we examined the expression of two key Nrf2
eﬀectors, SOD1 and SOD2, which catalyze the conversion of superoxide
to hydrogen peroxide. SOD1 is cytosolic, whereas SOD2 is localized in
the mitochondrial matrix [71]. While SOD1 expression was not
increased (Fig. 4 Aiii, Biii and Ciii), SOD2 immunoreactivity was
markedly elevated in the photoreceptor inner segments, where the
mitochondria reside (Fig. 4 Aii, Bii and Cii). Previous studies have
demonstrated the importance of both enzymes in maintaining the
retinal redox environment; however SOD2 appears to be more im-
portant for photoreceptor homeostasis. In Sod1 knockout mice,
Hashizume and colleagues observed delayed changes in the retinal
architecture compared to wt mice [72]. Inner nuclear layer (INL)
thinning became signiﬁcant (p < 0.01) at 30 weeks of age, while a less
signiﬁcant (p < 0.05) decrease in ONL thickness was observed only at
50 weeks of age, suggesting that SOD1 is more important for the health
of the INL, rather than the photoreceptors. Indeed, the loss of cells in
the outer retina may be a consequence of inner retinal cell death. In
comparison to this slow and progressive degeneration which aﬀects
mainly the inner layers of the retina, Sod2 knockout mice show
photoreceptor degeneration from 9 days old, compared to their wild
type counterparts [73]. Further support for this hypothesis comes from
Fig. 4. Norgestrel increases the expression of the antioxidants Nrf2 and SOD2, but not SOD1. Balb/c mice were given intraperitoneal injections of vehicle (veh) or vehicle containing
100 mg/kg norgestrel (norg) 1 h prior to light damage (LD) and were euthanized at 6 h, 24 h or 48 h post-LD. Approximately 4 h before being euthanasia, mice received two
intraperitoneal injections of 20 mg/kg dihydroethidine (DHE), 30 min apart. Ocular sections were obtained and assessed by microscopy as described in Methods. A; assessment of the
expression of Nrf2 (i), SOD2 (ii) and SOD1 (iii) 6 h post-LD in vehicle (veh) or norgestrel (norg) treated mice. B; assessment of the expression of Nrf2 (i), SOD2 (ii) and SOD1 (iii) 24 h
post-LD in vehicle (veh) or norgestrel (norg) treated mice. C; assessment of the expression of Nrf2 (i), SOD2 (ii) and SOD1 (iii) 48 h post-LD in vehicle (veh) or norgestrel (norg) treated
mice. Counter-ﬂuorescence of DHE (red) is also shown. Hoechst staining (blue) allows orientation of the retinal layers, and shows changes in ONL thickness following LD. PRL;
Photoreceptor layer, ONL; outer nuclear layer, OPL; outer plexiform layer, INL; inner nuclear layer, IPL; inner plexiform layer. D; graphical representation of Nrf2 or SOD2 ﬂuorescence
intensity in vehicle (veh) or norgestrel (norg) treated mice. Results are representative of at least n=3. Scale bar=50 µm. (For interpretation of the references to color in this ﬁgure legend,
the reader is referred to the web version of this article.)
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Fig. 5. Norgestrel increases phosphorylation of Nrf2 and its nuclear translocation. Balb/c mice were given intraperitoneal injections of vehicle (veh) or vehicle containing 100 mg/kg
norgestrel (norg) 1 h prior to light damage (LD) and were euthanized at 6 h, 24 h or 48 h post-LD. A; LD retinas were assessed for relative changes in nrf2 mRNA expression following
vehicle (veh) or norgestrel (norg) treatment. Relative expression was analyzed by means of real time (rt) PCR, with fold change compared to the geometric mean of three endogenous
reference genes (gapdh, hprt, β-actin). Results are representatives of n=2. B; sub-cellular fractionation was carried out on retinal lysates from mice treated with vehicle (veh) or
norgestrel (norg) and euthanized 6 h, 24 h and 48 h post-LD. Expression of phospho-Nrf2 (pNrf2) or total Nrf2 (Nrf2) in cytosolic and nuclear fractions was assessed by means of
western blot analyses. Equal loading of samples and veriﬁcation of the subcellular fractions were assessed by probing for cytosolic-localized GAPDH and nuclear-localized histone H3
(HH3). Western blot is representative of n=4. C; Approximately 4 h before being euthanized, mice received two intraperitoneal injections of 20 mg/kg dihydroethidine (DHE), 30 min
apart. Ocular sections were obtained and assessed by microscopy as described in Methods. pNrf2 expression (green) was assessed in vehicle (veh) or norgestrel (norg) treated mice at 6 h
(Ci), 24 h (Cii) and 48 h (Ciii) post-LD. Counter-ﬂuorescence of DHE (red) is also shown. Hoechst staining (blue) allows orientation of the retinal layers, but is removed from half of each
image to increase the clarity of pNrf2 staining. PRL; Photoreceptor layer, ONL; outer nuclear layer. Images are representative of at least n=3. Scale bar=50 µm. (For interpretation of the
references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
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a number of studies where SOD1 was found to be an important
antioxidant in the retinal ganglion cell (RGC) layer, the innermost layer
of the retina. SOD1-deﬁcient mice display increased ROS levels in the
RCG layer [74]. In another study, Sod1-null mice in which retinal
oxidative stress was induced, displayed TUNEL in the INL and RGCs
only [75]. Interestingly, Sod1 overexpressing mice have actually been
shown to display increased levels of ROS with accelerated photorecep-
tor degeneration [5]. The results presented here suggest that mito-
chondrial-derived ROS is an important consequence of light-induced
retinal damage, and that norgestrel can markedly reduce this toxicity
via up-regulation of Nrf2 and subsequently SOD2, enabling detoxiﬁca-
tion within the mitochondria which is necessary for preservation of
photoreceptor cell number and structure.
We next sought to investigate the mechanism of norgestrel-induced
Nrf2 expression. We ﬁrst examined nrf2 mRNA expression following
norgestrel, but found no change compared to vehicle (Fig. 5A).
Although norgestrel is a synthetic steroid hormone, lack of transcrip-
tional activity is not surprising given that it can act through the non-
classical receptor; progesterone receptor membrane component 1
(PGRMC1) [76]. Moreover, Nrf2 is known to be regulated almost
entirely at the post-translational level, being constitutively expressed
and maintained at basal levels by KEAP1-mediated turn-over [54].
Such basal expression enables Nrf2 to elicit a rapid and eﬃcient
response to stress stimuli, upon which it escapes KEAP1 and translo-
cates into the nucleus, bringing about transcription of various anti-
oxidant genes. A small population of Nrf2 is also believed to remain in
the nucleus, allowing constitutive basal expression of target genes
[77,78]. Cytosolic Nrf2 can be phosphorylated and thus activated by
PKC, which disrupts its interaction with KEAP1 [56,57]. Following
light-induced damage, norgestrel treated retinas display an elevated
population of phospho-Nrf2 within the nucleus (Fig. 5B). However, the
western blot analyses are that of whole retinas. Looking speciﬁcally at
the photoreceptors, there are marked increases in pNrf2 levels within
the ONLs of norgestrel treated mice, which is sustained up to 48 h
(Fig. 5C). These data suggest that norgestrel mediates the activation of
Nrf2 through PKC-phosphorylation, thereby bringing about an increase
in Nrf2 nuclear translocation and consequent antioxidant gene tran-
scription. Further work needs to be carried out to explore the link
between norgestrel and PKC, however other studies have shown that
progesterone can exert neuroprotective eﬀects via activation of PKC
[79,80].
Nrf2 also contains a phoshodegron, phosphorylation of which
promotes nuclear export and a return to basal antioxidant signaling.
A central regulator of Nrf2 in this manner is glycogen synthase kinase
3β (GSK3β) [55]. GSK3β phosphorylates and thus activates cytosolic
Fyn, allowing it to enter the nucleus where it in turn phosphorylates
and brings about the nuclear export of Nrf2 [81–83], resulting in Nrf2
re-binding KEAP1 and being rapidly degraded. Interestingly, we have
previously shown that norgestrel inhibits GSK3β [84], adding weight to
the results reported here.
In conclusion, this study supports previous work showing that
norgestrel is a potent neuroprotective agent in the compromised retina,
and provides strong in vivo evidence that norgestrel is also a powerful
antioxidant. We show how norgestrel markedly reduces mitochondrial-
derived ROS in the retina via post-translational regulation of the major
antioxidant transcription factor Nrf2 and its eﬀector protein SOD2.
These results highlight the potential of norgestrel as a therapeutic
option for RP and other retinal degenerative conditions, which will not
discriminate between genetic etiologies.
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